Johnson & Johnson Launches VIRTUGUIDE™ AI-Powered Patient-Matched Lapidus System in U.S. to Reduce Complexity in Bunion Surgery for Millions

Johnson & Johnson Launches VIRTUGUIDE™ AI-Powered Patient-Matched Lapidus System in U.S. to Reduce Complexity in Bunion Surgery for Millions

JNJ
Positive
Market
Johnson & Johnson Launches VIRTUGUIDE™ AI-Powered Patient-Matched Lapidus System in U.S. to Reduce Complexity in Bunion Surgery for Millions

Summary

Early VIRTUGUIDE™ surgeons report a 30-minute reduction in surgical time versus traditional treatment1 ,2 , *,** WEST CH...

Early VIRTUGUIDE™ surgeons report a 30-minute reduction in surgical time versus traditional treatment1 ,2 , ,* WEST CHESTER, Penn. , July 29, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) – Johnson & Johnson MedTech, a global leader in orthopaedic technologies and solutions, today announced the launch of the VIRTUGUIDE™ System.

Tags

JNJ
Related Articles
Massive Headwinds Are on the Horizon for Pharmaceutical Stocks, but Here Are 2 That Could Weather the Storm
JNJ
Positive
Boston Jury Hits Johnson & Johnson with Record $42M Verdict in Asbestos Baby Powder Case
JNJ
Neutral
Johnson & Johnson files with U.S. FDA to include new evidence in TREMFYA® (guselkumab) label as the only IL-23 inhibitor to demonstrate significant inhibition of joint structural damage in active psoriatic arthritis
JNJ
Positive